Molecular glues: drugging the ”undruggable”

Sjöberg Prize Laureate 2021 Benjamin L. Ebert, Harvard University, USA. From: Sjöberg Prize Lectures, 2022-06-13.

[@vedataslan6121]

VRD is the main treatment regimen in myeloma treatment and we use lenalidomid with proteosome inhibitor. according these mechanisms, proteosome inhibitors can inhibit effect of lenalidomide. there may be two mechanism to explain the additive effect of lenalidomide and proteosome inhibitors. first is that bortezomib as an proteosome inhibitor is short acting antmyeloma drug. so days in without borteomib lenalidomide has antimyeloma efect. second is that lenalidomide do not effect myeloma cells but effects T cells to attack myeloma cells. lenalidomid degrades IKZF1 and 2 so interleukin level raises and this activates the inactivated t cells in myeloma microenvironment. according to the studies on CAR-T cell effect of lenalidomide this mechanism can explain. weekly bortezomib use and ommiting lenalidomid in bortezomib day

[@bardacha100]

This is a magical presentation ! Love the sharing of science with such a great talk !

[@resonatingvoice1]

Wonderful talk and such a good introduction... thanks

[@Rene-uz3eb]

Best chance to understand the body is from an engineering perspective. While it is infinitely complex thanks to evolution, it still amounts to a machine so it has to make sense eg in terms of hierarchical organization etc.